Avantor, Inc. (NYSE:AVTR) Stock Has Average Price Target of $14.77 According to Analysts

Avantor, Inc. (NYSE:AVTR) has been given a consensus rating of “Hold” by the sixteen brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $14.77.

AVTR has been the topic of a number of recent analyst reports. Jefferies Financial Group upgraded Avantor from an “underperform” rating to a “hold” rating and set a $13.00 price objective on the stock in a research report on Wednesday, July 29th. Morgan Stanley boosted their price objective on shares of Avantor from $14.00 to $15.00 and gave the company an “equal weight” rating in a research report on Tuesday, October 13th. Evercore set a $17.00 target price on shares of Avantor in a research note on Wednesday, October 28th. Stifel Nicolaus raised their price objective on shares of Avantor from $15.00 to $18.00 and gave the stock a “hold” rating in a report on Thursday, October 29th. Finally, Royal Bank Of Canada lifted their price objective on Avantor from $14.00 to $17.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 28th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Ethic Inc. boosted its stake in Avantor by 158.9% during the 3rd quarter. Ethic Inc. now owns 55,706 shares of the company’s stock valued at $838,000 after purchasing an additional 34,186 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Avantor by 3.8% in the 3rd quarter. Parallel Advisors LLC now owns 19,033 shares of the company’s stock worth $286,000 after purchasing an additional 693 shares in the last quarter. Chicago Partners Investment Group LLC increased its holdings in shares of Avantor by 57.8% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 53,137 shares of the company’s stock worth $919,000 after purchasing an additional 19,455 shares in the last quarter. True Freedom Investing LLC purchased a new position in shares of Avantor in the third quarter worth $587,000. Finally, Pinkerton Wealth LLC purchased a new position in shares of Avantor in the third quarter worth $324,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Price Performance

Shares of Avantor stock opened at $15.61 on Friday. The firm has a market cap of $10.58 billion, a PE ratio of 31.22, a price-to-earnings-growth ratio of 7.06 and a beta of 0.95. Avantor has a 12-month low of $7.26 and a 12-month high of $17.45. The company has a quick ratio of 1.27, a current ratio of 1.89 and a debt-to-equity ratio of 0.63. The company’s fifty day simple moving average is $15.54 and its two-hundred day simple moving average is $11.27.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, October 28th. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.21 by $0.01. Avantor had a net margin of 5.08% and a return on equity of 9.79%. The firm had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period in the prior year, the firm posted $0.22 earnings per share. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. As a group, equities analysts expect that Avantor will post 0.82 EPS for the current year.

Avantor Company Profile

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.